CRDF is currently developing the following drugs: Bevacizumab, Folfiri, Onvansertib, Folfox, Bevacizumab, Folfiri, Onvansertib, Fluorouracil, Leucovorin, Nanoliposomal Irinotecan, Onvansertib. These drug candidates are in various stages of clinical development as the company works toward FDA approval.